A Clinician's View of Engineering and Technology in Intensive Care - Model-based Therapeutics and Patient Outcomes by Shaw, G.M. et al.
     
A Clinician’s View of Engineering and Technology in Intensive Care - Model-
based Therapeutics and Patient Outcomes  
 
Shaw GM*, Chase JG**, Hann CE** 
 
*Christchurch Hospital Intensive Care Unit, Christchurch, New Zealand 
 (Tel: e-mail:Geoff.Shaw@cdhb.govt.nz). 
**Department of Mechanical Engineering, University of Canterbury, Christchurch, New Zealand  
 ( e-mail:Chris.Hann@canterbury.ac.nz, Geoff.Chase@canterbury.ac.nz)  
 
Abstract: This paper presents a summary of previous and current research at the Christchurch Hospital 
Intensive Care Unit from the point of view of an intensive care specialist who has worked in the field for 
the past 18 years. All the major areas of sedation-agitation, cardiovascular and mechanical ventilation 
management, glucose control and sepsis diagnosis are covered as case studies, including model 
developments and clinical outcomes. The overall approach is described as “Model-based Therapeutics” 
and has the philosophy of a “one method fits all” rather than the more typical “one size fits all” approach. 
The research presented shows the way forward to next generation health care, where current medical 
equipment, sensors and drugs are used in a smarter way to develop patient-specific diagnosis and therapy.       
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1. INTRODUCTION 
Intensive care is one of the most challenging areas of modern 
medicine. With aging populations and increased complexity 
of care, the social and economic burden of intensive care is 
increasing, and accounts for 10%, or more, of all healthcare 
costs, or 1-1.5% of GDP in western countries. Economically, 
these costs are beginning to bring some healthcare systems to 
their knees.  
It is also a technology laden area of medicine, with 
mechanical ventilators, semi-automated infusion pumps, and 
a wide range of sensors. However, while the technology used 
continues to evolve and improve incrementally, it has not 
changed radically in 30 years. Thus, improving patient 
outcomes, while restraining cost, in the intensive care unit 
(ICU) of the next 10 years, will revolve around how we use 
that technology and maximize its potential  
Importantly, the technology and how clinical staff interpret 
the information it provides, have not improved patient 
outcomes or productivity in care while the main cost of 
intensive care is in clinical staff. Thus, while technology, 
particularly computers, has driven productivity revolutions in 
many industries, including parts of medicine, it has failed to 
do so in the ICU. This paper examines the means by which 
this issue can be addressed, and how there is a need to 
develop technologies that overcome these obstacles. 
In a typical intensive care there is very little time to diagnose 
a patient’s condition and determine the proper treatment. 
Patient’s lives ultimately can depend on clinical staff doing 
the right thing at the right time. In addition, while patients are 
continually monitored, they are only infrequently examined 
or diagnosed, and at set points in time. Thus, a great deal of 
potentially valuable information is lost, and the variability 
that defines the critically ill patient can wreak extensive 
havoc. What is needed is the ability to accurately and  
continuously inform bedside clinical staff of what is really 
going on with their patient – something that modern 
technologies and physiological knowledge can do in 
combination. Thus, it’s an area which creative and adaptive 
solutions using engineering and computational methods, 
mixed with clinical and physiological knowledge, can save 
lives, time and cost. 
The Department of Intensive Care in Christchurch, New 
Zealand has seen the development of highly innovative health 
care initiatives including glucose control, cardiovascular and 
ventilation management, agitation sensing and optimal 
sedation and real-time sepsis diagnostics (Blakemore et al 
2008, Chase et al 2008, Chase et al 2007, Lonergan 2006a, 
Lonergan 2006b, Hann et al 2005a, Hann et al 2008, 
LeCompte et al 2009, Shaw et al 2007,Smith et al 2004, 
Hann et al 2005b, Starfinger et al 2008, Starfinger et al 2007, 
Sundaresan et al 2009, Chase et al 2004, Shaw et al 2003, 
Chase et al 2004, Becouze et al 2007). The glucose control 
protocol developed has lead to a clinical practice change with 
significant savings on mortality, cost and overall patient 
outcome (Chase et al 2008). 
The overall approach is referred to as model-based 
therapeutics or MBT (Chase et al 2007, Lonergan 2006a, 
Lonergan 2006b, Hann et al 2008). The philosophy is to 
develop a “one-method-fits all” rather than static or fixed 
‘one-size-fits all’ approaches that predominate in results in 
randomised clinical trials (RCTs).  RCTs produce outcomes 
 
 
     
 
of risk based on treatments given.  Thus, when this evidence 
is translated into clinical practice, patients can only be  
treated for the risk of  a particular disease or condition.  The 
result: treatments are given blindly for an indefinite period of 
time for diseases or conditions that often don’t exist.  Thus, 
the “evidence” gained from RCTs can not be used to predict 
outcomes of treatments titrated to patient-specific responses. 
The goal of MBT is to develop patient-specific diagnoses and 
therapies that make more effective use of existing sensors and 
technologies.  
The common approach in intensive care to patient 
management is to ‘cover all bases’ which typically leads to 
over prescribing of therapies. For example, patients tend to be 
over-feed, over-sedated, kept on mechanical ventilation for 
too long, and given far more drugs (e.g. antibiotics and 
inotropes) than is necessary. Hence, significant costs can be 
incurred without benefitting patients (Mullner et al 2004). 
The primary problem is that the measurements and patient 
responses to various therapies given are very complex, even 
for highly trained specialists, who have to make a best 
“guess” at what is going on. Hence, this process is often ‘hit 
and miss’ and takes time (and error) to get right. For sicker 
patients who are less tolerant of incorrect treatments, there 
may be little time to make a correct diagnosis. It is often 
impossible to know, exactly, the real causes of the particular 
physiological dysfunction. For example there can be several 
different conditions affecting the circulation that look the 
same on the intensive care monitors. 
Doctors are helped by using other diagnostic tools, such as 
cardiac echocardiography, lab tests and computerized 
tomography (CT) scans. However, these measurements are 
not available immediately at the bedside, and they require 
expert technical skills and interpretation, and thus add cost. 
Finally, no intermittent diagnostic test can truly tell the nurse 
or doctor what is going on physiologically as it happens (in 
real-time). 
What is required are methods to turn a range of numbers and 
sensor outcomes into a clear and well-understood 
physiological picture of patient condition. This approach 
takes best advantage of the available technology to translate 
physiological and clinical knowledge in textbooks and 
research, directly to the bedside in a way that thus best 
matches clinical training and knowledge. From this outcome, 
we can create improved productivity in care. 
 
2. CASE STUDIES 
2.1 Agitation/sedation: 
Sedative delivery in intensive care is fundamental to effective 
agitation management and is the basis for providing comfort 
and relief to the critically ill. The yearly cost in the US of 
sedatives and analgesics in the ICU was estimated to be $0.8-
1.2B US in 2001 (Fraser and Riker, 2001). 
A landmark study (Kress et al, 2000) of sedation interruption 
showed significant reductions in the time spent on 
mechanical ventilation and the length of stay. Another study 
(Girard et al, 2008) has shown that sedative interruption in 
combination with successful spontaneous breathing trials 
resulted in earlier discharges and increased 12 month 
survival.  A recent review concludes that systematic 
interventions to improve sedation practice and maintain 
patients at an optimal sedation level in the ICU may improve 
patient outcomes and optimize resource usage (Jackson, et al 
2010). However, when sedation is switched off when patients 
are not ready to be removed from mechanical ventilatory 
support, this resulted in an mortality de Wit et al, 2008. This 
demonstrates the dangers of simply reducing sedation in a 
simple protocol without proper knowledge of the underlying 
dynamics. In other words, it’s not what drug or what dose 
that’s given, it’s how it’s delivered. 
Specifically, an objective, physiologically-based, agitation 
scale, models or understanding of agitation-sedation 
dynamics, and effective, well-understood infusion protocols 
are needed Prior research has developed and clinically 
validated an agitation index (Chase et al 2004) with further 
refinements to include detection of grimacing and 
quantification (Becouze et al 2007). Agitation-Sedation 
Dynamic models have also been developed based on clinical 
data (Chase et al 2004) and have shown significant potential 
for the development of improved protocols (Rudge, et al 
2005). This approach allows patient-specific drug delivery 
and should be the focus of new research. 
 
2.2 Model-based cardiac diagnosis and therapy: 
The approach to cardiovascular management in critical care 
commonly involves titrating drugs and giving fluids based 
mainly on arterial pressure but with some other 
measurements including central venous pressure, ECG and 
SPO2 waveforms. The interpretation of this diverse and rather 
limited data set is very difficult and thus clinical staff 
primarily rely on experience and intuition to make a 
diagnosis or administer a treatment.  
For example, the main reason for giving inotropes is to 
improve cardiac muscle function. Hence, to see the real 
physiological effect of inotropes requires analysis of left 
ventricular pressure-volume (PV) loops, which has been well 
studied in the literature (Guyton 2000). Yet, even though 
registrars and nurses get exposed to PV loops from in their 
training, this concept is often completely lost when they 
reach clinical practice. A recent (unpublished) data audit has 
shown that even with arterial pressure essentially clamped, 
the left ventricular power index, which assesses the power of 
the heart to pump blood (the key outcome metric)  can vary 

















Figure 1: Plot of power index with MAP essentially clamped. 
 
Therefore, there is an urgent need for a more physiological 
representation of the data displayed on intensive care 
monitors which could be achieved by an appropriate patient 
specific cardiovascular model. Previous work (e.g. Starfinger 
et al 2008, Starfinger et al 2007), has developed and validated 
a lumped parameter cardiac model on animal models. This 
success has led to the development of clinical trials. More 
specifically, animal studies have already shown the ability to: 
• Diagnose pulmonary embolism (PE) (Starfinger et al 
2007) 
• Diagnose septic shock (Starfinger et al 2008a) 
• Capture the impact of hypovolemia (Starfinger et al 
2008a) 
• Capture the impact PEEP on circulation (Starfinger 
et al 2008b) 
• Capture the affect of adrenaline and inotropes on 
circulation to optimise titration (Chase et al 2010) 
These results cover many common diagnostic difficulties and 
therapeutic interactions. They are also have unique 
capabilities. Importantly, the ability to clearly define, in a 
physiological sense, these issues can dramatically improve 
diagnosis, therapy selection and care in intensive care. In 
particular, because cardiovascular dysfunction is a leading 
cause of ICU mortality, these tools can have immediate 
impact. 
 
2.3  Management of Mechanical Ventilation (MV):  
Acute Respiratory Dysfunction Syndrome (ARDS) is a major 
cause of hospitalization with mortality rates from 30-70% 
Bersten et al (2002). Despite many recent studies on MV 
treatment there are no well established methods to determine 
an optimal, patient-specific positive end expiratory pressure 
(PEEP), a critical MV setting, or any other ventilator settings. 
The objective of this research is to develop a simple model 
that can be run at the bedside with minimal intervention to 
optimise PEEP and MV therapy.  
Clinical trials are currently in progress, to validate the 
model’s ability to predict the outcome of a change in PEEP 
on the recruitment of lung units or alveoli. Further, as seen in 
Figure 2, the model can assess the impact of PEEP on net 
recruitment (Sundaresan et al 2009), which is a primary 
physiological and clinical end-point or goal.  
MV is used to improve recruitment of lung units to aid 
recovery, while minimising excessive tidal volumes and/or 
pressures that can lead to ventilator induced lung injury 
(VILI) of healthy units. Hence, the goal is to use PEEP to 
prevent derecruitment of lung units at end expiration 
(preventing their collapse and associated damage due to 
continued recruitment and derecruitment). Hence, the ability 
to noninvasively capture net recruitment at any PEEP without 
the need for other technologies, and to do so at any time, will 
provide significant insight to clinical management of MV. 
 
Figure 2: Example patient fit and prediction (left) and volume 
responsiveness of inspiratory (lower) and expiratory (upper) 
limbs. Asterisk indicates predicted values, lines show the 
linear trend prediction.  
 
Figure 3 shows this model in action on an initial clinical trial. 
The figure shows net increase in recruitment for an intensive 
care patient as a function of PEEP. It is clear that a PEEP of 
20cmH2O is the point at which net recruitment is maximised 
and thus an optimal, physiologically and clinically relevant 
PEEP value. Importantly, the initial clinical setting for this 
trial was a PEEP of 10cmH2O, a much lower value that had 
not been changed in some time, while the patient condition 
had evolved, illustrating a further advantage in that such a 
patient-specific, model-based method can be used frequently 
to evaluate and track patient condition. 





























     
 
It is clear from Figure 3 that one would clinically never add 
PEEP past a point where net increase in recruitment did not 
change, as it risks VILI, as well as depressing venous return 
and cardiac output for no gain (or potential loss) in lung 
function through increased dead space. Thus, the model can 
provide clear, physiologically and clinically relevant insight 
that is currently completely blind to the clinical staff 
managing MV. 
 
2.4  Glucose control and sepsis diagnosis 
Hyperglycemia is prevalent in critical care, and leads to 
increased risk of myocardial infarction, organ failure, 
infection and death. The hyperglycemic critically ill patient is 
also highly dynamic, with excessive, highly variable insulin 
resistance due to their condition. Tight glycemic control 
(TGC) can reduce mortality if blood glucose can be kept in a 
target range consistently.  
Several studies have reduced mortality up to 40% in patients 
who stay 3-5 days or longer in the ICU (Chase et al 2008, 
Van den Berghe et al 2006, Krinsley 2004). However, several 
other studies have failed to replicate these results (NICE-
SUGAR study 2009). The difficulty of providing real-time, 
adaptive and patient-specific TGC that is effective has 
prevented this therapy from being widely used.  
In particular, most protocols are fixed and static, focusing on 
insulin dosing in response to blood glucose levels (Chase et 
al 2006). These protocols thus completely fail to address 
patient-specific and time varying insulin resistance. Thus, 
what works well for some patients can fail completely for 
others. This difficulty is a perfect example of the difference 
between one size fits all, static approaches to care, and the 
need for adaptive patient specific therapy. 
The Christchurch ICU currently uses a model-derived, 
adaptive and patient-specific system called SPRINT that has 
reduced mortality 20-40% for patients staying 3-5 days or 
longer (Chase et al 2008). The system was derived from 
metabolic system models validated in a wide range of clinical 
studies in this ICU, and designed specifically for TGC (Chase 
et al 2007). It thus directly titrates not off blood glucose level 
but off patient-specific insulin sensitivity, as derived from the 
nutrition and insulin interventions and resulting blood 
glucose response.  
Equally importantly, the control has been tight enough to 
significantly reduce sepsis and infection. In addition, recent 
studies have shown that it significantly reduced the number, 
severity and rate of organ failure in patients using SPRINT 
versus a retrospective, matched cohort, indicating that this 
reduction provided the foundation for improved mortality. 
Finally, reduced organ failure resulted in reduced costs, and 
SPRINT has a net cost savings per patient treated of 
NZ$1052. Surveys showed that net clinical burden also 
decreased. Thus, SPRINT provides better outcomes and 
reduced cost, through a model-derived system, illustrating the 
power of MBT. 
Further improvements, including the use of model-based 
control are forthcoming to provide further savings and 
productivity gains. In particular stochastic models of patient 
variability  can be used to provide guaranteed levels of safety 
from hypoglycaemia (LeCompte et al 2009). This stochastic 
targeted (STAR) TGC is currently already in use in the 
Christchurch Womens Hospital Neonatal ICU (LeCompte et 
al 2009). These models and systems provide direct 
physiological picture and assessment of the patient’s real-
time metabolic status, making the optimisation of insulin 
therapy clearer, more efficient for staff, and more effective 
for the patient. 
Finally, as a glimpse of the future potential of MBT in ICU, 
these clear physiological pictures of insulin resistance status 
can be used in other diagnostics. Specifically, patients with 
sepsis exhibit significantly reduced and variable insulin 
sensitivity. Thus, this model-based metric, along with other 
readily available clinical metrics can be used to provide a 
real-time diagnosis of sepsis (Blakemore et al 2008). In 
particular, where new sepsis develops in critically ill patients, 
this task can be highly challenging to distinguish other non-
septic causes of inflammation. Hence, the clear physiological 
picture created of metabolic status can be used to improve 




The Christchurch Department of Intensive Care has 
developed a unique clinical-engineering collaboration with 
the Department of Mechanical Engineering at the University 
of Canterbury. This collaboration is highly multi-disciplinary, 
and has led to the development of clinically validated models 
of each individual major physiological system for diagnosis 
and decision support. Clinical outcomes and significant cost 
savings have already been achieved, and clinical trials are in 
progress in every major area of the ICU. Hence, there is 
significant potential to link all the main diagnostic and 
therapeutic methods. The vision for the future is a fully 
unified, model-based therapeutics system which integrates all 
drug delivery devices and sensors and provides significantly 
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